Slide 1: Investor Presentation
Investor Presentation 22 September 2026
Slide 2: Disclaimer and important notice 1 of 2
Disclaimer and important notice 1 of 2 This presentation contains summary information about Rua Bioscience Limited (Rua) and its activities that is current as at the date of this presentation. Information of a general nature The information in this presentation is of a general nature and does not pu
Slide 3: Disclaimer and important notice 2 of 2
Disclaimer and important notice 2 of 2 Past performance Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) future Rua performance, including future financial position or share price performanc
Slide 4: Kia ora, and thank you
Kia ora, and thank you A note from the Chair and Chief Executive • Last year we asked for your support to take Rua through a pivotal stage of growth. You supported us, and that support has helped us build the platform we have today. • Much has changed over the past 12 months. Revenue has grown, our
Slide 5: Same kaupapa, stronger evidence
Same kaupapa, stronger evidence We remain focused on our strategy • A capital-light model anchored in genetics and distribution, not cultivation or manufacturing infrastructure. • Outsourcing commercial manufacturing has helped cut operating expenditure as revenue increases. • New distribution and o
Slide 6: Our Strategy
01 Our Strategy
Slide 7: Genetics and mātauranga at the core
Genetics and mātauranga at the core Our community links is our point of difference • Our edge starts with genetics selected in Te Tairāwhiti - cannabinoid and terpene profiles unique to Rua. • We work with legacy growers, and we're proud of those connections - access to varieties available nowhere e
Slide 8: Rua is doing medicinal cannabis differently in the NZ market
Rua is doing medicinal cannabis differently in the NZ market Rua operates in a targeted segment of the market with the lowest capital requirements. This means we can leverage our expertise to deliver scalable value with trusted partners. Rua’s point of difference Rua has outsourced production to bes
Slide 9: From genetics to global markets
From genetics to global markets How genetics become revenue Six markets, one platform • Clones exported live - Canada • Aotearoa, New Zealand - our home market • Licensed and grown out - Aotearoa, Canada • Australia - second-largest medicinal cannabis market globally • Finished product via distribut
Slide 10: Investment Highlights
02 Investment Highlights
Slide 11: Evidence across six markets
Evidence across six markets The strategy is translating into commercial activity across established and new markets. AUSTRALIA UNITED KINGDOM AOTEAROA NZ Revenue almost doubled ~NZ$10m expected (over 2yrs) Share and revenue up Strong clinic relationships continue to Largest export agreement to date;
Slide 12: Rua today: the strategy is producing commercial evidence
Rua today: the strategy is producing commercial evidence The business has moved from building the platform to demonstrating that the platform works, on a fixed cost base. $2.9m +71% 3% ↓ 5 ~NZ$10m FY26 revenue Customer revenue Opex International cannabis UK agreement growth markets up 54% year-on-ye
Slide 13: Largest export supply agreement to date
Largest export supply agreement to date Commercial validation of our strategy Why this matters ~$NZ10m New Zealand-grown product → NZ growers + partners → UK distribution anticipated revenue over an initial two-year period assuming Rua can fund the necessary The commercial model is already in place
Slide 14: Three research programmes, all rooted in Te Tairāwhiti
Three research programmes, all rooted in Te Tairāwhiti Rua is already working with partners on the next generation of botanical products. Wairuakohu Project Tū Wairua Project Cytisine from kōwhai Radula liverwort Psilocybin-containing mushrooms A native source of an established medicine A liverwort
Slide 15: The capability we built for cannabis is not limited to cannabis
The capability we built for cannabis is not limited to cannabis Longer-term research using our core knowledge and experience. Contribution to FY27 revenue Now Medicinal cannabis ~100% of revenue FY26 – FY28 Five markets, established distribution, unique genetics. This is the business, and it is wher
Slide 16: Growing without losing our kaupapa
Growing without losing our kaupapa Compassionate Access Programme Student Scholarship Programme Leveraging support from partners and local Through Rua‘s scholarship programme, assisting Te community, Rua are now supporting up to 52 Tairawhiti students through their studies, they have patients each m
Slide 17: Why We're Raising
03 Why We're Raising
Slide 18: We need further capital to grow our revenue
We need further capital to grow our revenue • Growth at this pace needs working capital - inventory has to be funded ahead of sales as we scale into established international markets. • We have funded that working capital requirement since our last raise through a disciplined mix of equity and debt.
Slide 19: Capital converts demand into revenue
Capital converts demand into revenue The capital raised will be used primarily to fund inventory and working capital ahead of confirmed and anticipated sales growth. Particularly to fulfil the UK agreement, meet growing demand in Australia and Aotearoa, New Zealand, and support market entry in Canad
Slide 20: The Offer
04 The Offer
Slide 21: Offer Details
Offer Details • 1 for 3 pro-rata renounceable entitlement offer to raise up to ~$2.8 million (if fully subscribed) Offer Size and • Up to approximately 113.1m new Rua shares to be issued (33% of existing shares on issue) Structure • Offer structure similar to 2025 rights offer with shortfall shares
Slide 22: Offer Timetable
Offer Timetable Announcement of the Offer Tuesday, 22 September 2026 Rights Trading Opens Monday, 28 September 2026 (Rights trading commences on the NZX Main Board) Record Date 5pm, Tuesday, 29 September 2026 (for determining eligibility to participate in the offer and entitlements) Opening Date of